Jinling Pharmaceutical Company Limited (000919.SZ) has announced that its controlling subsidiary, Chizhou Dongsheng Pharmaceutical Co., Ltd., has received the "Chemical Drug Active Pharmaceutical Ingredient Marketing Authorization Approval Notice" for Arorolol Hydrochloride from the National Medical Products Administration. This approval marks a significant milestone for the company's pharmaceutical portfolio expansion.

Arorolol Hydrochloride is a receptor blocker that simultaneously inhibits both alpha and beta receptors. Its finished drug products are primarily indicated for the treatment of essential hypertension (mild to moderate) and angina pectoris. The approval is expected to strengthen the subsidiary's position in the cardiovascular therapeutic segment.

This regulatory clearance follows the company's ongoing efforts to diversify its active pharmaceutical ingredient offerings and enhance its competitive edge in the domestic market. The company noted that the approval will contribute to its long-term growth strategy, subject to market conditions and operational execution.